In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

The only difference between the two is that the FDA has approved Zepbound for weight loss and Mounjaro for type 2 diabetes. These prescription medications are part of the same class of drugs as ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity, are no longer in shortage, The agency’s decision will ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... we keep a strict separation between our sales teams and authors to remove any pressure or ...

Sales of Eli Lilly's (LLY) blockbuster diabetes and weight loss drugs, Mounjaro and Zepbound, are very strong, but they're not quite as robust as the company and analysts had anticipated in Q4.

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro ... duopoly between LLY and NVO, Zepbound ...

Zepbound is another brand name for tirzepatide — and this one is FDA-approved for weight loss. So, how does Mounjaro work ... there was no significant difference between the 5-milligram dose ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows compounding ...